CBAY CymaBay Therapeutics Inc.

12.61
+0.23  (+2%)
Previous Close 12.38
Open 12.44
Price To Book 3.36
Market Cap 866231882
Shares 68,694,043
Volume 1,896,617
Short Ratio
Av. Daily Volume 684,125

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 planned - to be initiated by Kowa Pharmaceuticals.
Arhalofenate
Gout
Phase 3 top-line data due in 2021.
Seladelpar
Primary biliary cholangitis (PBC)
Phase 2b top-line data due 2Q 2019.
Seladelpar
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019
  2. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
  3. Edited Transcript of CBAY earnings conference call or presentation 8-May-19 8:30pm GMT
  4. Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc (CBAY)
  5. CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update
  6. CymaBay Therapeutics Announces Multiple Presentations at DDW 2019
  7. Genfit, Cymbay Hope to Crack Large Liver Disease Market
  8. CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8
  9. If You Had Bought CymaBay Therapeutics (NASDAQ:CBAY) Stock Three Years Ago, You Could Pocket A 703% Gain Today
  10. CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress™ 2019
  11. CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference™ 2019
  12. Market Trends Toward New Normal in Louisiana-Pacific, The Michaels Companies, VEREIT, CymaBay Therapeutics, CareDx, and Harsco — Emerging Consolidated Expectations, Analyst Ratings
  13. CymaBay Therapeutics to Present at Upcoming Investor Conferences in March
  14. CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
  15. CymaBay Announces Pricing of Public Offering of Common Stock
  16. Edited Transcript of CBAY earnings conference call or presentation 28-Feb-19 9:30pm GMT
  17. CymaBay Announces Proposed Public Offering of Common Stock
  18. CymaBay Therapeutics Inc (CBAY) Q4 2018 Earnings Conference Call Transcript
  19. CymaBay Reports Fourth Quarter and Fiscal Year End 2018 Financial Results and Provides Corporate Update
  20. Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries — New Research Emphasizes Economic Growth